Anti-GD2 Antibody with GM-CSF, Interleukin-2, and Isotretinoin for Neuroblastoma
Open accessThe DOI matches its Crossref record; 39 of the 39 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Preclinical and preliminary clinical data indicate that ch14.18, a monoclonal antibody against the tumor-associated disialoganglioside GD2, has activity against neuroblastoma and that such activity is enhanced when ch14.18 is combined with granulocyte-macrophage colony-stimulating factor (GM-CSF) or interleukin-2. We conducted a study to determine whether adding ch14.18, GM-CSF, and interleukin-2 to standard isotretinoin therapy after intensive multimodal therapy would improve outcomes in high-risk neuroblastoma. METHODS: Patients with high-risk neuroblastoma who had a response to induction therapy and stem-cell transplantation were randomly assigned, in a 1:1 ratio, to receive standard therapy (six cycles of isotretinoin) or immunotherapy (six cycles of isotretinoin and five concomitant cycles of ch14.18 in combination with alternating GM-CSF and interleukin-2). Event-free survival and overall survival were compared between the immunotherapy group and the standard-therapy group, on an intention-to-treat basis. RESULTS: A total of 226 eligible patients were randomly assigned to a treatment group. In the immunotherapy group, a total of 52% of patients had pain of grade 3, 4, or 5, and 23% and 25% of patients had capillary leak syndrome and hypersensitivity reactions, respectively. With 61% of the number of expected events observed, the study met the criteria for early stopping owing to efficacy. The median duration of follow-up was 2.1 years. Immunotherapy was superior to standard therapy with regard to rates of event-free survival (66±5% vs. 46±5% at 2 years, P=0.01) and overall survival (86±4% vs. 75±5% at 2 years, P=0.02 without adjustment for interim analyses). CONCLUSIONS: Immunotherapy with ch14.18, GM-CSF, and interleukin-2 was associated with a significantly improved outcome as compared with standard therapy in patients with high-risk neuroblastoma. (Funded by the National Institutes of Health and the Food and Drug Administration; ClinicalTrials.gov number, NCT00026312.)
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Some immunotherapies have shown promise in this setting, such as dinutuximab administered in combination with cytotoxic therapy in relapsed/refractory neuroblastoma3,4.”
From A Phase I/II Trial of Nivolumab plus Ipilimumab in Children and Young Adults with Relapsed/Refractory Solid Tumors: A Children's Oncology Group Study ADVL1412 (2022) · cites this paper as [4]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Nonparametric Estimation from Incomplete Observations
Kaplan, E. L., & Meier, P. (1992) · Springer Series in Statistics · doi:10.1007/978-1-4612-4380-9_25 · Cited by 45,181
Nonparametric Estimation from Incomplete Observations
Kaplan, E. L., & Meier, P. (1958) · Journal of the American Statistical Association · doi:10.1080/01621459.1958.10501452 · Cited by 39,158
Discrete sequential boundaries for clinical trials
GORDON LAN, K. K., & DEMETS, D. L. (1983) · Biometrika · doi:10.1093/biomet/70.3.659 · Cited by 2,310 · cited 1×
“Pain 50 (37) 30 (24) 23 (19) 33 (29) 15 (14) 4 (4)”
Discrete Sequential Boundaries for Clinical Trials
Lan, K. K. G., & DeMets, D. L. (1983) · Biometrika · doi:10.2307/2336502 · Cited by 2,310
Maris, J. M., Hogarty, M. D., Bagatell, R., & Cohn, S. L. (2007) · The Lancet · doi:10.1016/s0140-6736(07)60983-0 · Cited by 2,032
Self-citationMatthay, K. K., Villablanca, J. G., Seeger, R. C., Stram, D. O., Harris, R. E., Ramsay, N. K., Swift, P., Shimada, H., Black, C. T., Brodeur, G. M., et al. (1999) · New England Journal of Medicine · doi:10.1056/nejm199910143411601 · Cited by 1,898 · cited 2×
“Hypersensitivity reaction 14 (10) 33 (26) 6 (5) 29 (25) 13 (12) 3 (3)”
Self-citationWeng, W.-K., & Levy, R. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.05.013 · Cited by 1,300 · cited 1×
“Complete response 38 (34) 40 (35) 78 (35) 61±7 86±5”
Musolino, A., Naldi, N., Bortesi, B., Pezzuolo, D., Capelletti, M., Missale, G., Laccabue, D., Zerbini, A., Camisa, R., Bisagni, G., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.14.8957 · Cited by 981
Matthay, K. K., Reynolds, C. P., Seeger, R. C., Shimada, H., Adkins, E. S., Haas-Kogan, D., Gerbing, R. B., London, W. B., & Villablanca, J. G. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2007.13.8925 · Cited by 858 · cited 1×
“Pain 50 (37) 30 (24) 23 (19) 33 (29) 15 (14) 4 (4)”
Self-citationAdoptive cell therapy for the treatment of patients with metastatic melanoma
Rosenberg, S. A., & Dudley, M. E. (2009) · Current Opinion in Immunology · doi:10.1016/j.coi.2009.03.002 · Cited by 595
Research works printed but not linked: 10
- Schulz G, 1984, Cancer Res, 44, 5914
- Yu AL, 1997, Proc Am Soc Oncol, 6, 1846
- Barker E, 1991, Cancer Res, 51, 144
- Albertini MR, 1997, Clin Cancer Res, 3, 1277
- Hank JA, 1990, Cancer Res, 50, 5234
- 10.2307/2281868 · doi:10.2307/2281868 · Paper page
- Greenwood M, 1926, Rep Public Health Med Subj (Lond), 33, 1
- Barker E, 1993, Cancer Res, 53, 362
- Dallegri F, 1989, Clin Exp Immunol, 77, 58
- Simon T, 2009, Pediatr Blood Cancer, 53, 708
Cited by
Items 801–900 of 1,000
Advances in new targets for immunotherapy of small cell lung cancer
Zheng, Z., Liu, J., Ma, J., Kang, R., Liu, Z., & Yu, J. (2023) · Thoracic Cancer · doi:10.1111/1759-7714.15178 · Cited by 21
“97,98 Yoshida et al. found that the expression of GD2 varied greatly in lung cancer, with characteristic expression in SCLC and low or no expression in NSCLC. 99 Therefore, GD2 is an attractive target for the immunotherapy of SCLC. GD2 promotes cancer cell proliferation, adhesion, migration, and…”
BackgroundMohseni, R., Sharif, P. M., Behfar, M., Shojaei, S., Shoae‐Hassani, A., Jafari, L., Khosravi, A., Nikfetrat, Z., & Hamidieh, A. A. (2024) · Scientific Reports · doi:10.1038/s41598-024-70958-7 · Cited by 21
Natural killer cells in neuroblastoma: immunological insights and therapeutic perspectives
Radoš, M., Landegger, A., Schmutzler, L., Rabidou, K., Taschner‐Mandl, S., & Fetahu, I. S. (2024) · Cancer and Metastasis Reviews · doi:10.1007/s10555-024-10212-8 · Cited by 19
“This treatment modality has resulted in significantly improved survival rates for NB patients and has become the standard treatment regimen [33–35].”
BackgroundNeuroblastoma: Issues in Transplantation
Grupp, S. A., Asgharzadeh, S., & Yanik, G. A. (2012) · Transplantation and Cellular Therapy · doi:10.1016/j.bbmt.2011.10.020 · Cited by 18
“18, IL-2, GM-CSF and cisretinoic acid) based on recent data from the COG ANBL0032 study, which showed a superior outcome in patients who received this immunotherapy-based treatment(14).”
MethodSelf-citationSchrey, D., Vaidya, S. J., Levine, D., Pearson, A. D. J., & Moreno, L. (2015) · Journal of Pediatric Hematology/Oncology · doi:10.1097/mph.0000000000000308 · Cited by 18
“8) 3 (30) 1 (10) 1 (25) Lines of subsequent treatment (median [range]) 2 (1-6) 2 (1-6) 2 (1-3) 2 (2-3) No.”
BackgroundEffects of Cisplatin Electrochemotherapy on Human Neuroblastoma Cells
Eşmekaya, M. A., Kayhan, H., Coşkun, A., & Canseven, A. G. (2016) · The Journal of Membrane Biology · doi:10.1007/s00232-016-9891-4 · Cited by 19
“Cisplatin is most commonly used drug in the treatment of neuroblastoma (Dorr and Von Hoff 1994; Yu et al. 2010; Piskareva et al. 2011).”
BackgroundSteineck, A., MacKenzie, J. D., & Twist, C. J. (2016) · Pediatric Blood & Cancer · doi:10.1002/pbc.26124 · Cited by 19
Exosomes: Novel Players of Therapy Resistance in Neuroblastoma
Richard, H., Pokhrel, A., Chava, S. P., Pathania, A. S., Katta, S. S., & Challagundla, K. B. (2020) · Advances in experimental medicine and biology · doi:10.1007/978-3-030-50224-9_5 · Cited by 19
Yu, J., Chan, S., Fung, M. K.-L., & Chan, G. (2021) · BMC Cancer · doi:10.1186/s12885-021-08090-2 · Cited by 19
Su, T., Qin, X., Dohmae, N., Wei, F., Furutani, Y., Kojima, S., & Yu, W. (2021) · Metabolites · doi:10.3390/metabo11030167 · Cited by 19
“In addition, a monoclonal anti-GD2 antibody, 14G2a, against neuroblastoma induced the activation of p53 in neuroblastoma cells [47,51].”
BackgroundHeide, S., Masliah‐Planchon, J., Isidor, B., Guimier, A., Bodet, D., Coze, C., Deville, A., Thebault, E., Pasquier, C. J., Cassagnau, E., et al. (2015) · Pediatric Blood & Cancer · doi:10.1002/pbc.25723 · Cited by 18
Cheung, B. B., Tan, O., Koach, J., Liu, B., Shum, M., Carter, D. R., Sutton, S. K., Po’uha, S. T., Chesler, L., Haber, M., et al. (2015) · Molecular Oncology · doi:10.1016/j.molonc.2015.04.005 · Cited by 19
Siebert, N., Eger, C., Seidel, D., Jüttner, M., & Lode, H. N. (2014) · Journal of Immunological Methods · doi:10.1016/j.jim.2014.04.001 · Cited by 18
“18 have shown improved outcome in NB-patients (Simon et al., 2004; Simon et al., 2011; Yu et al., 2010).”
BackgroundWedekind, M. F., Haworth, K. B., Arnold, M., Stanek, J. R., Lee, D. A., & Cripe, T. P. (2018) · Pediatric Blood & Cancer · doi:10.1002/pbc.27313 · Cited by 18
Choi, Y. B., Son, M. H., Cho, H. W., Ma, Y., Lee, J. W., Kang, E., Yoo, K. H., Her, J. H., Lim, O., Jung, M.-Y., et al. (2019) · PLoS ONE · doi:10.1371/journal.pone.0225998 · Cited by 18
“Therefore, further efforts will be needed to improve long-term outcomes without increasing GVHD, such as the use of anti-GD2 antibody with NKI [43], TCRα/ β-depleted [44], CD45RA-depleted grafts [45], or chimeric antigen receptor-modified NK cells [46].”
BackgroundCash, T., Marachelian, A., DuBois, S. G., Chi, Y., Baregamyan, A., Groshen, S. G., Jonus, H. C., Shamirian, A., Crowley, M., Goodarzian, F., et al. (2025) · Journal of Clinical Oncology · doi:10.1200/jco-24-02612 · Cited by 17
Self-citationGray, J. C., Weston, R., Owens, C., Cañete, A., Gambart, M., Wilde, B. D., Nysom, K., van Eijkelenburg, N. K. A., Ladenstein, R. L., Castellano, A., et al. (2025) · Journal of Clinical Oncology · doi:10.1200/jco-25-01868 · Cited by 17
Difluoromethylornithine (DFMO) and Neuroblastoma: A Review
Tangella, A. V., Gajre, A., Chirumamilla, P. C., & Rathhan, P. V. (2023) · Cureus · doi:10.7759/cureus.37680 · Cited by 17
“This article provides a thorough analysis of the research on DFMO and how it can be used to treat neuroblastoma with or following the standard MSKCC/SIOPEN/COG regimen.”
BackgroundMethodInfluentialCellular immunotherapy for pediatric solid tumors
Hegde, M. G., Moll, A. J., Byrd, T. T., Louis, C. U., & Ahmed, N. M. (2014) · Cytotherapy · doi:10.1016/j.jcyt.2014.05.019 · Cited by 18
“18, IL-2 and GM-CSF was associated with an improvement in both 2-year event-free and overall survival (46% versus 66% and 75% versus 86%, respectively) (80).”
BackgroundMorandi, F., Croce, M., Cangemi, G., Barco, S., Rigo, V., Carlini, B., Amoroso, L., Pistoia, V., Ferrini, S., & Corrias, M. V. (2015) · Journal of Immunology Research · doi:10.1155/2015/718975 · Cited by 18
“anti-GD2 mAb with IL-2 or GM-CSF can activate NK-cell or granulocyte mediated antibody dependent cell-mediated cytotoxicity (ADCC) against NB cells and lead to improved survival [14].”
BackgroundGershan, J. A., Barr, K. M., Weber, J. J., Jing, W., & Johnson, B. D. (2015) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-015-0071-3 · Cited by 17
“Based on a 2-year 20 % increase in event-free survival, anti-GD2 disialoganglioside antibody in combination with interleukin-2 (IL-2) and granulocyte colony stimulating factor (GM-CSF) has been added to standard of care protocols [3].”
BackgroundI-131-mIBG therapy in neuroblastoma: established role and prospective applications
Schmidt, M. C., Hero, B., & Simon, T. (2016) · Clinical and Translational Imaging · doi:10.1007/s40336-016-0173-z · Cited by 19
“Despite aggressive treatment regimens, high-risk neuroblastoma continues to have a devastating mortality rate of more than 40 % [7, 8] and 5-year overall survival of patients with stage 4 neuroblastoma is only 30–50 % [7–9] The addition of anti-GD2-antibodies has improved this poor prognosis to some extent [10].”
BackgroundGu, X., Hua, Z., Dong, Y., Zhan, Y., Zhang, X., Tian, W., Liu, Z., Thiele, C. J., & Li, Z. (2017) · Scientific Reports · doi:10.1038/srep42062 · Cited by 20
Fan, Q., Kopp, S. J., Connolly, S. A., Muller, W. J., & Longnecker, R. (2017) · Scientific Reports · doi:10.1038/srep43712 · Cited by 17
Ceylan, K., Jahns, L. J., Lode, B. N., Ehlert, K., Kietz, S., Troschke‐Meurer, S., Siebert, N., & Lode, H. N. (2018) · Pediatric Blood & Cancer · doi:10.1002/pbc.26967 · Cited by 17
Canzonetta, C., Pelosi, A., Matteo, S. D., Veneziani, I., Tumino, N., Vacca, P., Munari, E., Pezzullo, M., Theuer, C. P., Vito, R. D., et al. (2021) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2020-001313 · Cited by 19
CAR T Cell Therapy’s Potential for Pediatric Brain Tumors
Thomas, P., Galopin, N., Bonerandi, E., Clemenceau, B., Fougeray, S., & Birklé, S. (2021) · Cancers · doi:10.3390/cancers13215445 · Cited by 17
“In this regard, it should be kept in mind that GD2-specific therapeutic antibody infusions are frequently associated with severe neurotoxicity due to GD2 expression in peripheral nerves and the brain parenchyma [46,47].”
BackgroundMatthay, K. K., Hylton, J., Penumarthy, N. L., Khattab, M., Soh, S. Y., Hoa, N. T. K., Alcasabas, A. P., Fawzy, M., Saab, R. H., Khan, M. S., et al. (2022) · Pediatric Blood & Cancer · doi:10.1002/pbc.29568 · Cited by 19
Self-citationImmunotherapy Associated Neurotoxicity in Pediatric Oncology
Shalabi, H., Nellan, A., Shah, N. N., & Gust, J. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.836452 · Cited by 20
“One notable example of how immunotherapy has changed the treatment paradigm for a high-risk pediatric solid tumor is the success of the anti-GD2 antibody, dinutuximab, which is FDA approved as part of first line therapy for high-risk neuroblastoma patients (42).”
BackgroundImmunotherapy with anti‐G D2 monoclonal antibody in infants with high‐risk neuroblastoma
Kushner, B. H., Modak, S. I., Kramer, K., Basu, E. M., Cardenas, F. I., Roberts, S. S., & Cheung, N. V. (2022) · International Journal of Cancer · doi:10.1002/ijc.34233 · Cited by 17
“11-15 In contrast, at Memorial Sloan Kettering Cancer Center (MSK), many infants have received anti-GD2 mAbs for several reasons, including (1) 3F8 has been used in between cycles of induction chemotherapy(4,16); (2) ASCT was discontinued for HR-NB after 2003(17,18); and (3) this immunotherapy starts before local radi…”
MethodImmunotherapies of retinoblastoma: Effective methods for preserving vision in the future
Wang, L., Li, S., Mei, J., & Ye, L. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.949193 · Cited by 20
“After being tested in clinical trials, anti-GD2 monoclonal antibodies proved their safety and efficacy suggesting that GD2 could be an essential immune target for the treatment of RB (21).”
BackgroundSiebert, N., Seidel, D., Eger, C., Brackrock, D., Reker, D., Schmidt, M., & Lode, H. N. (2013) · Journal of Immunological Methods · doi:10.1016/j.jim.2013.09.008 · Cited by 19
Targeted therapy in pediatric and adolescent oncology
Bernstein, M. L. (2011) · Cancer · doi:10.1002/cncr.26050 · Cited by 17
“5).(36) A study gathering further information to support a licensing application is in progress.”
BackgroundSoni, S., Pai, V. B., Gross, T. G., & Ranalli, M. A. (2013) · Pediatric Transplantation · doi:10.1111/petr.12202 · Cited by 17
“18 anti-GD2 antibody plus cis-retinoic acid had a two-yr EFS rate of 66% ( 5%) compared with a 46% ( 5%) two-yr EFS for patients randomized to receive cis-retinoic acid alone (4).”
BackgroundResultBending the Cost Curve in Childhood Cancer
Russell, H. V., & Bernhardt, M. B. (2016) · Current Hematologic Malignancy Reports · doi:10.1007/s11899-016-0332-3 · Cited by 17
MYCN-amplified stage 2/3 neuroblastoma: excellent survival in the era of anti-GD2 immunotherapy
Kushner, B. H., LaQuaglia, M. P., Modak, S. I., Wolden, S. L., Basu, E. M., Roberts, S. S., Kramer, K., Yataghene, K., Cheung, I. Y., & Cheung, N. V. (2017) · Oncotarget · doi:10.18632/oncotarget.20513 · Cited by 18
“However, reports showing a benefit do not include [20], or do not provide details on [21], stage 2/3 patients.”
BackgroundLangemann, D., Trochimiuk, M., Appl, B., Hundsdoerfer, P., Reinshagen, K., & Eschenburg, G. (2017) · Oncotarget · doi:10.18632/oncotarget.21193 · Cited by 19
A strategy for the selection of monovalent antibodies that span protein dimer interfaces
Spangler, J. B., Moraga, I., Jude, K. M., Savvides, C. S., & García, K. C. (2019) · Journal of Biological Chemistry · doi:10.1074/jbc.ra119.009213 · Cited by 17
Ornell, K. J., Taylor, J. S., Zeki, J. C., Ikegaki, N., Shimada, H., Coburn, J. M., & Chiu, B. (2020) · Cancer Medicine · doi:10.1002/cam4.2936 · Cited by 18
Self-citationŻebrowska, U., Balwierz, W. A., Wechowski, J., & Wieczorek, A. (2024) · Targeted Oncology · doi:10.1007/s11523-024-01033-4 · Cited by 19
“The efficacy of this approach was demonstrated in large co-operative trials with COG (ANBL0032) [14] and SIOPEN (HR-NBL1/SIOPEN) [15], in which all patients had undergone MAT+ASCT prior to maintenance therapy.”
MethodFederico, S. M., Brady, S. L., Pappo, A. S., Wu, J., Mao, S., McPherson, V. J., Young, A., Furman, W. L., Kaufman, R. A., & Kaste, S. C. (2015) · Pediatric Blood & Cancer · doi:10.1002/pbc.25400 · Cited by 16
Role of Natural Killer Cells in HIV-Associated Malignancies
Leal, F. E., Premeaux, T. A., Abdel‐Mohsen, M., & Ndhlovu, L. C. (2017) · Frontiers in Immunology · doi:10.3389/fimmu.2017.00315 · Cited by 18
Zhao, P., Aguilar, A. E., Lee, J. Y., Paul, L. A., Suh, J. H., Puri, L., Zhang, M., Beckstead, J. A., Witkowski, A., Ryan, R. O., et al. (2018) · Investigational New Drugs · doi:10.1007/s10637-017-0558-5 · Cited by 16
“antibody-dependent cellular cytotoxicity (ADCC) and complement-dependent cell cytotoxicity (CDC) [1, 4, 16, 17].”
I-131 mIBG Scintigraphy Curie Versus SIOPEN Scoring: Prognostic Value in Stage 4 Neuroblastoma
Riaz, S., Bashir, H., Khan, S. J., & Qazi, A. Q. (2018) · Molecular Imaging and Radionuclide Therapy · doi:10.4274/mirt.52533 · Cited by 16
Surface expression of the immunotherapeutic target GD2 in osteosarcoma depends on cell confluency
Wiebel, M., Kailayangiri, S., Altvater, B., Meltzer, J., Grobe, K., Kupich, S., & Rössig, C. (2021) · Cancer Reports · doi:10.1002/cnr2.1394 · Cited by 18
“GD2 was found to be a safe therapeutic target for antibodies and CAR T cells in neuroblastoma, where it is abundantly expressed.(9,10) Immunohistochemistry studies have found aberrant expression of GD2 also in proportions of patients with Ewing sarcoma(11) and OS,(12-14) with preserved expression at recurrence.”
BackgroundSIRPα-specific monoclonal antibody enables antibody-dependent phagocytosis of neuroblastoma cells
Bahri, M., Kailayangiri, S., Vermeulen, S., Galopin, N., Rössig, C., Paris, F., Fougeray, S., & Birklé, S. (2021) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-021-02968-7 · Cited by 16
“Maintenance immunotherapy with anti-GD2 mAbs combined with IL-2 and 13-cis-RA has increased the proportion of relapse-free survival in children achieving complete remissions but fails to prevent relapses in about 40% of patients with this cancer, has only modest activity against measurable disease, and is associated w…”
BackgroundInfluentialNeuroblastoma survivors at risk for developing subsequent neoplasms: A systematic review
Westerveld, A. S. R., van Dalen, E. C., Asogwa, O. A., Koopman, M. M. W., Papadakis, V., Laureys, G., van der Pal, H. J. H., Kremer, L. C. M., Tytgat, G. A. M., & Teepen, J. C. (2022) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2022.102355 · Cited by 18
Yu, E. Y., Cheung, N. V., & Lue, N. F. (2022) · Journal of Hematology & Oncology · doi:10.1186/s13045-022-01337-w · Cited by 18
He, J., Munir, F., Ragoonanan, D. S., Zaky, W. T., Khazal, S. J., Tewari, P., Fueyo-Margareto, J., Gomez‐Manzano, C., & Jiang, H. (2023) · Immuno · doi:10.3390/immuno3010004 · Cited by 17
“Dinutuximab, an antidisialoganglioside GD2 chimeric monoclonal antibody, is the only FDA-approved monoclonal antibody for pediatric solid tumors [13].”
BackgroundNabbi, A., Beck, P., Delaidelli, A., Oldridge, D. A., Sudhaman, S., Zhu, K., Yang, S. Y. C., Mulder, D. T., Bruce, J. P., Paulson, J. N., et al. (2023) · Genome Medicine · doi:10.1186/s13073-023-01219-x · Cited by 16
“Addition of a monoclonal antibody targeting disialoganglioside GD2, granulocyte–macrophage colony-stimulating factor (GM-CSF) and interleukin-2 to standard therapy (isotretinoin) has been shown to improve overall survival of children with high-risk neuroblastoma treated with intensive multimodal therapy [4, 5].”
BackgroundUnguru, Y., Joffe, S., Fernandez, C. V., & Yu, A. L.-T. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.47.1227 · Cited by 17
Self-citationCappel, C., Huenecke, S., Suemmerer, A., Erben, S., Rettinger, E., Pfirrmann, V., Heinze, A., Zimmermann, O. L., Klingebiel, T. E., Ullrich, E., et al. (2016) · Pediatric Blood & Cancer · doi:10.1002/pbc.26147 · Cited by 18
Human and murine IL2 receptors differentially respond to the human-IL2 component of immunocytokines
Horta, Z. P., Saseedhar, S., Rakhmilevich, A. L., Carmichael, L. L., Hank, J. A., Boyden, M., Gillies, S. D., & Sondel, P. M. (2016) · OncoImmunology · doi:10.1080/2162402x.2016.1238538 · Cited by 16
“Therapy with an anti-disialoganglioside (GD2) reactive mAb, in combination with IL2 and GM-CSF, provides clinical benefit to some patients with GD2C tumors.(1) The hu14.”
BackgroundSelf-citationNovel Immunotherapeutic Approaches for Neuroblastoma and Malignant Melanoma
Morandi, F., Frassoni, F., Ponzoni, M., & Brignole, C. (2018) · Journal of Immunology Research · doi:10.1155/2018/8097398 · Cited by 17
PD-1/PD-L1 blockade in paediatric cancers: What does the future hold?
Moreno-Vicente, J., Beers, S. A., & Gray, J. C. (2019) · Cancer Letters · doi:10.1016/j.canlet.2019.04.025 · Cited by 16
Avitabile, M., Lasorsa, V. A., Cantalupo, S., Cardinale, A., Cimmino, F., Montella, A., Capasso, D., Haupt, R., Amoroso, L., Garaventa, A., et al. (2020) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.15058 · Cited by 18
CAMKV Is a Candidate Immunotherapeutic Target in MYCN Amplified Neuroblastoma
Sussman, R. T., Rokita, J. L., Huang, K. Y., Raman, P., Rathi, K. S., Martínez, D., Bosse, K. R., Lane, M. V., Hart, L. S., Bhatti, T. R., et al. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.00302 · Cited by 16
“significantly prolonged relapse free survival when used after achieving a first response to standard therapy, leading to regulatory approval in the United States and Europe (3).”
BackgroundSelf-citationLee, E., Lee, J. W., Lee, B., Park, K., Shim, J., Yoo, K. H., Koo, H. H., Sung, K. W., & Park, W. (2020) · BMC Medical Genomics · doi:10.1186/s12920-020-00819-5 · Cited by 19
Mora, J., Castañeda, A., Colombo, M., Gorostegui, M., Gómez, F., Mañé, S., Santa‐María, V., Garraus, M., Macías, N., Pérez‐Jaume, S., et al. (2021) · Cancers · doi:10.3390/cancers13061264 · Cited by 18
“18 (dinutuximab) combined with cytokines and 13-cis-RA improved the survival rates compared with 13-cis-RA alone in the post-consolidation phase [28].”
BackgroundTargeted Isotretinoin in Neuroblastoma: Kinetics, Genetics, or Absorption
Matthay, K. K. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-3313 · Cited by 16
“havebeen shown to improveoutcomes in randomized trials (2, 3).”
BackgroundSelf-citationReed, D. R., Mascarenhas, L., Manning, K., Hale, G. A., Goldberg, J., Gill, J. B., Sandler, E. S., Isakoff, M. S., Smith, T., Caracciolo, J. T., et al. (2015) · Cancer Medicine · doi:10.1002/cam4.598 · Cited by 16
Horwacik, I., Durbas, M., Boratyn, E., Sawicka, A., Węgrzyn, P., Krzanik, S., Górka, A., Drożniak, J., Augustyniak, E., Kowalczyk, A., et al. (2015) · Acta Biochimica Polonica · doi:10.18388/abp.2015_1035 · Cited by 16
When Innovation and Commercialization Collide: A Patient Advocate View in Neuroblastoma
Bird, N., Knox, L., Palmer, A., Heenen, D. L., Blanc, P., Scobie, N., & Ludwinski, D. (2021) · Journal of Clinical Oncology · doi:10.1200/jco.21.01916 · Cited by 16
Hu, Y., Li, M., Wang, J., Xu, Y., Ye, H., Zhang, L., Luo, Q., Zhen, Z., Lü, S., Huang, J., et al. (2023) · International Journal of Oncology · doi:10.3892/ijo.2023.5602 · Cited by 15
“At present, monoclonal GD2 specific antibodies have significantly improved the survival rates of patients with high‑risk NB (3,4); however, the high costs associated with the use of GD2 monoclonal antibody for immunotherapy hinders its widespread use in patients in low‑ and middle‑income countries.”
BackgroundSafety and efficacy of dinutuximab in the treatment of neuroblastoma: A review
Mohd, A. B., Mohd, O. B., Alabdallat, Y. J., Al-Dwairy, S., Ghannam, R. A., Hanaqtah, B. M., & Albakri, K. A. (2023) · Journal of Research in Medical Sciences · doi:10.4103/jrms.jrms_727_22 · Cited by 15
“[15,16] Similar results were reported by Keyel and Reynolds.”
BackgroundResultInfluentialEichholz, T., Heubach, F., Arendt, A.-M., Seitz, C. M., Brecht, I. B., Ebinger, M., Flaadt, T., Süßkind, D., Richter, L. E., Hülsenbeck, I., et al. (2024) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-023-03587-0 · Cited by 15
“Targeting GD2 with mAbs improves survival in neuroblastoma [8–10] and is standard of care in high-risk, relapsed or refractory disease [11, 12].”
BackgroundBhat, A. M., Mohapatra, B. C., Luan, H., Mushtaq, I., Chakraborty, S., Kumar, S., Wu, W., Nolan, B., Dutta, S., Storck, M. D., et al. (2024) · Scientific Reports · doi:10.1038/s41598-024-60052-3 · Cited by 15
Cell state plasticity in neuroblastoma
Durbin, A. D., & Versteeg, R. (2024) · EJC Paediatric Oncology · doi:10.1016/j.ejcped.2024.100184 · Cited by 19
At the frontier of progress for paediatric oncology: the neuroblastoma paradigm
Moreno, L., Marshall, L. V., & Pearson, A. D. J. (2013) · British Medical Bulletin · doi:10.1093/bmb/ldt033 · Cited by 17
Ng, L. W., Wong, K., Wu, C.-L. A., Sposto, R., & Olch, A. J. (2018) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2018.02.015 · Cited by 15
Zebrafish as a Neuroblastoma Model: Progress Made, Promise for the Future
Li, S., Yeo, K. S., Levee, T. M., Howe, C. J., Her, Z. P., & Zhu, S. (2021) · Cells · doi:10.3390/cells10030580 · Cited by 15
“This immunotherapy has been approved by FDA for the treatment of patients with high-risk NB who achieve at least a partial response to prior first-line multiagent, multimodality therapy [12].”
BackgroundMethodSzanto, C. L., Cornel, A. M., Tamminga, S. M., Delemarre, E. M., de Koning, C. C. H., van den Beemt, D. A. M. H., Dünnebach, E., Tas, M. L., Dierselhuis, M. P., Tytgat, G. A. M., et al. (2021) · Cancers · doi:10.3390/cancers13092096 · Cited by 16
“Even though IT increased 2 year EFS and overall survival (OS) [3], relapses are still observed in the majority of patients.”
BackgroundVariable Expression of the Disialoganglioside GD2 in Breast Cancer Molecular Subtypes
Erber, R., Kailayangiri, S., Huebner, H., Ruebner, M., Hartmann, A., Häberle, L., Meyer, J., Völkl, S., Mackensen, A., Landgraf, L., et al. (2021) · Cancers · doi:10.3390/cancers13215577 · Cited by 16
“However, GD2 antibody therapy can cause substantial toxicities in children, including capillary leak syndrome and neuropathic pain [20,21].”
BackgroundInfluentialHighlights into historical and current immune interventions for cancer
Cole, K., Al-Kadhimi, Z. S., & Talmadge, J. E. (2023) · International Immunopharmacology · doi:10.1016/j.intimp.2023.109882 · Cited by 15
Immunotherapy in Pediatric Malignancies: Current Status and Future Perspectives
Capitini, C. M., Otto, M., DeSantes, K. B., & Sondel, P. M. (2014) · Future Oncology · doi:10.2217/fon.14.62 · Cited by 19
Self-citationOxaliplatin and Doxorubicin for Relapsed or Refractory High-Risk Neuroblastoma
Tran, H. C., Marachelian, A., Venkatramani, R., Jubran, R. F., & Mascarenhas, L. (2014) · Pediatric Hematology and Oncology · doi:10.3109/08880018.2014.983624 · Cited by 15
“Cisplatin and doxorubicin are used in standard induction therapy for advanced stage high risk neuroblastoma [3, 4].”
BackgroundTaunk, N. K., Kushner, B. H., Ibanez, K., & Wolden, S. L. (2016) · Pediatric Blood & Cancer · doi:10.1002/pbc.25863 · Cited by 15
Natural Killer Cells to the Attack: Combination Therapy against Neuroblastoma
Zenarruzabeitia, O., Vitallé, J., Astigarraga, I., & Borrego, F. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-2478 · Cited by 15
“New therapeutic options involve targeting of GD2, which is highly expressed on neuroblastoma cells (7).”
BackgroundVillablanca, J. G., Ji, L., Shapira‐Lewinson, A., Marachelian, A., Shimada, H., Hawkins, R. A., Pampaloni, M. H., Lai, H., Goodarzian, F., Sposto, R., et al. (2018) · Pediatric Blood & Cancer · doi:10.1002/pbc.26940 · Cited by 15
“Survival for patients with high-risk neuroblastoma (HR-NB) remains 50%, 1 despite improvements with myeloablative therapy, isotretinoin, 2,3 and immunotherapy, 4 emphasizing the need for more effective therapies.”
Self-citationKannagi, R., Cai, B., Huang, H., Chao, C.-C., & Sakuma, K. (2018) · Methods in molecular biology · doi:10.1007/978-1-4939-8552-4_6 · Cited by 15
Cabozantinib for relapsed neuroblastoma: Single institution case series
Perisa, M. P., Storey, M., Streby, K. A., Ranalli, M. A., Skeens, M. A., & Shah, N. (2020) · Pediatric Blood & Cancer · doi:10.1002/pbc.28317 · Cited by 15
Zobel, M. J., Zamora, A. K., Wu, H., Sun, J., Lascano, D., Malvar, J., Wang, L. L., Sheard, M. A., Seeger, R. C., & Kim, E. S. (2020) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2020-001560 · Cited by 16
Self-citationLiao, Y., Hung, T., Tung, J. K., Yu, J., Hsu, Y., Hung, J., & Yu, A. L.-T. (2021) · Journal of Personalized Medicine · doi:10.3390/jpm11020122 · Cited by 15
“While the addition of anti-disialoganglioside (GD2)-based immunotherapy has increased event-free and overall survival in patients with high-risk NBL [3], there is still room for improvement.”
BackgroundSelf-citationStrijker, J. G. M., Pscheid, R., Drent, E., van der Hoek, J. J. F., Koopmans, B., Ober, K., van Hooff, S. R., Kholosy, W. M., Cornel, A. M., Coomans, C., et al. (2021) · Journal of Personalized Medicine · doi:10.3390/jpm11090923 · Cited by 16
“Even though implementation of Dinutuximab into the neuroblastoma treatment protocol has significantly improved survival rates, the 5-year survival rate of ~50% for high-risk patients is still dismal and leaves room for improvement [3].”
BackgroundInfluentialMethodological advances in the discovery of novel neuroblastoma therapeutics
Segura, M. F., Soriano, A., Roma, J. M., Piskareva, O., Jiménez, C., Boloix, A., Fletcher, J. I., Haber, M., Gray, J. C., Cerdá-Alberich, L., et al. (2021) · Expert Opinion on Drug Discovery · doi:10.1080/17460441.2022.2002297 · Cited by 16
“(2010), demonstrating a significant improvement in survival in children with high-risk neuroblastoma receiving anti-GD2 (dinutuximab) based immunotherapy in addition to standard treatment [83].”
BackgroundNeuroblastoma in a pediatric patient with a microduplication of 2p involving the MYCN locus
Mater, D. V., Knelson, E. H., Kaiser‐Rogers, K. A., & Armstrong, M. B. (2013) · American Journal of Medical Genetics Part A · doi:10.1002/ajmg.a.35766 · Cited by 15
“He was then enrolled on COG protocol ANBL0931 and received anti-GD2 antibody therapy [Yu et al., 2010].”
MethodMora, J., Cruz, O., Lavarino, C. E., Ríos, J., Vancells, M., Parareda, A., Salvador, H., Suñol, M., Carrasco, R., Guillén, A., et al. (2015) · Clinical & Translational Oncology · doi:10.1007/s12094-014-1273-8 · Cited by 17
“18 together with GM-CSF and IL-2 has become the standard of care for high-risk NB after a randomized trial at COG institutions [16].”
BackgroundKinoshita, S., Ishii, M., Ando, J., Kimura, T., Yamaguchi, T., Harada, S., Takahashi, F., Nakashima, K., Nakazawa, Y., Yamazaki, S., et al. (2024) · Cancer Research Communications · doi:10.1158/2767-9764.crc-23-0259 · Cited by 18
Friedman, D. N., Goodman, P. J., Leisenring, W. M., Diller, L., Cohn, S. L., Howell, R. M., Smith, S. A., Tonorezos, E. S., Wolden, S. L., Neglia, J. P., et al. (2024) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djae062 · Cited by 15
Self-citationPolyamine Inhibition with DFMO: Shifting the Paradigm in Neuroblastoma Therapy
Schramm, J. W., Sholler, C., Menachery, L., Vazquez, L., & Sholler, G. S. (2025) · Journal of Clinical Medicine · doi:10.3390/jcm14041068 · Cited by 14
“The treatment involves induction chemotherapy with surgery after cycle 4 or 5, followed by consolidation therapy including autologous stem cell transplant (single or tandem) and radiation therapy; this is followed by maintenance with anti-GD2 immunotherapy and retinoic acid [1–4].”
RBM39 degrader invigorates innate immunity to eradicate neuroblastoma despite cancer cell plasticity
Singh, S. V., Fang, J., Jin, H., de Velde, L.-A. V., Cortes, A., Chen, J., Natarajan, S., Poon, E., Wu, Q., Morton, C. L., et al. (2025) · Nature Communications · doi:10.1038/s41467-025-63979-x · Cited by 16
“And last, when GD2 immunotherapy is applied, NK cells elicit antibody-dependent cellular cytotoxicity (ADCC) to further enhance the killing of neuroblastoma cells.”
InfluentialImmunocombination Therapy for High-Risk Neuroblastoma
Kroesen, M., Lindau, D., Hoogerbrugge, P. M., & Adema, G. J. (2012) · Immunotherapy · doi:10.2217/imt.11.169 · Cited by 14
Progress towards personalized therapeutics: biologic- and risk-directed therapy for neuroblastoma
Gustafson, W. C., & Matthay, K. K. (2011) · Expert Review of Neurotherapeutics · doi:10.1586/ern.11.103 · Cited by 15
Self-citationStrategies to Improve Chimeric Antigen Receptor Therapies for Neuroblastoma
Sawaisorn, P., Atjanasuppat, K., Anurathapan, U., Chutipongtanate, S., & Hongeng, S. (2020) · Vaccines · doi:10.3390/vaccines8040753 · Cited by 16
“The use of this antibody-based therapy was compiled into a therapeutic protocol for high-risk neuroblastoma patients and revealed promising results [9,10].”
MethodChiang, A. W. T., Baghdassarian, H., Kellman, B. P., Bao, B., Sorrentino, J. T., Liang, C., Kuo, C., Masson, H. O., & Lewis, N. E. (2021) · Journal of Biomedical Science · doi:10.1186/s12929-021-00746-2 · Cited by 17
Neuroblastoma GD2 Expression and Computational Analysis of Aptamer-Based Bioaffinity Targeting
Sabbih, G. O., & Danquah, M. K. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22169101 · Cited by 14
“18 (dinutuximab) in conjunction with granulocyte-macrophage colony-stimulating factor (GM-CSF), interleukin-2 (IL-2), and isotretinoin [6].”
BackgroundSynthetic Heterocyclic Derivatives as Kinase Inhibitors Tested for the Treatment of Neuroblastoma
Musumeci, F., Cianciusi, A., D’Agostino, I., Grossi, G., Carbone, A., & Schenone, S. (2021) · Molecules · doi:10.3390/molecules26237069 · Cited by 14
“18) is a chimeric monoclonal antibody approved by FDA in 2015 for Molecules 2021, 26, 7069 3 of 49 the treatment of HR-NB, in combination with 13-cis-retinoic acid (RA), interleukin-2 (IL-2), and granulocyte-macrophage colony-stimulating factor (GM-CSF) [19].”
MethodThe origins of resident macrophages in mammary gland influence the tumorigenesis of breast cancer
Yang, Y., Hou, J., Liu, J., Bhushan, S., & Wu, G. (2022) · International Immunopharmacology · doi:10.1016/j.intimp.2022.109047 · Cited by 16
Advances in the treatment of pediatric solid tumors: A 50‐year perspective
LaQuaglia, M. P., & Gerstle, J. T. (2022) · Journal of Surgical Oncology · doi:10.1002/jso.27038 · Cited by 14
“Yu et al.(20) showed that event‐free survival”
Campbell, K. M., Kao, P., Naranjo, A. H., Kamijo, T., Ramanujachar, R., London, W. B., & DuBois, S. G. (2022) · Pediatric Blood & Cancer · doi:10.1002/pbc.30054 · Cited by 14
Self-citation
Metadata
- Authors
- Yu, A. L., Gilman, A. L., Ozkaynak, M. F., London, W. B., Kreissman, S. G., Chen, H. X., Smith, M., Anderson, B., Villablanca, J. G., Matthay, K. K., Shimada, H., Grupp, S. A., Seeger, R., Reynolds, C. P., Buxton, A., Reisfeld, R. A., Gillies, S. D., Cohn, S. L., Maris, J. M., & Sondel, P. M.
- Affiliations
- University of California San Diego (US)
- Levine Children's Hospital (US)
- Boston Children's Hospital (US)
- Duke Medical Center (US)
- National Institutes of Health (US)
- University of Southern California (US)
- University of California, San Francisco (US)
- Children's Hospital of Philadelphia (US)
- Texas Tech University (US)
- Children's Oncology Group (US)
- Scripps Research Institute (US)
- University of Chicago (US)
- University of Wisconsin–Madison (US)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2010-09-30
- Volume
- 363
- Issue
- 14
- Pages
- 1324-1334
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- PMC
- PMC3086629
- OpenAlex
- W2130465135
- Cited by
- 1,835
- References
- 38
- Citations by year
- 2026: 99 · 2025: 98 · 2024: 124 · 2023: 133 · 2022: 142 · 2021: 151 · 2020: 156 · 2019: 107 · 2018: 107 · 2017: 139 · 2016: 105 · 2015: 115 · 2014: 95 · 2013: 103 · 2012: 92
- FWCI
- 49.55
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Funders
- National Institutes of Health (CA98543)
- U.S. Food and Drug Administration (FD-R-002319)
- National Cancer Institute (CA‐98413, U10 CA-98413, U10-CA98543, U10CA098413, R01CA032685, U10CA29139, U10CA029139, U10CA098543, CA-98543)
- Topics
- Health Sciences › Medicine › Oncology › Neuroblastoma Research and Treatments
- Health Sciences › Medicine › Oncology › Glioma Diagnosis and Treatment
- Health Sciences › Medicine › Clinical Neurology › Neurofibromatosis and Schwannoma Cases
- Keywords
- neuroblastoma, GD2, GM-CSF, interleukin-2, isotretinoin, immunotherapy, high-risk neuroblastoma, event-free survival, overall survival, disialoganglioside, stem cell transplantation, multimodal therapy
- MeSH terms
- Antibodies, Monoclonal, Antineoplastic Agents, Child, Child, Preschool, Combined Modality Therapy, Drug Therapy, Combination, Gangliosides, Humans, Immunotherapy, Infant, Interleukin-2, Neuroblastoma, Isotretinoin, Survival Analysis, Granulocyte-Macrophage Colony-Stimulating Factor, Stem Cell Transplantation, Intention to Treat Analysis
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.